ArticleFrontiers in cardiovascular medicine2025
Triglyceride-glucose index as a predictor of cardiovascular multimorbidity: a prospective cohort study.
Article in Frontiers in cardiovascular medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: The triglyceride-glucose (TyG) index is a recognized marker of insulin resistance, yet its role in the dynamic progression from cardiovascular disease (CVD) to cardiovascular multimorbidity (CVM) remains unclear. This study aimed to evaluate the association between the TyG index and transitions from a CVD-free state to first CVD and subsequently to CVM. Methods: In this prospective cohort study, we included participants from the Shanghai Suburban Adult Cohort who were free of CVD at baseline (2016). The TyG index was measured at baseline. Disease transitions were tracked over a median follow-up of 6.26 years. First CVD event was defined as the initial occurrence of coronary heart disease (CHD), stroke, or heart failure (HF), and CVM was defined as the presence of two or more of these conditions. Multi-state models were used to assess the association between the TyG index and transitions across health states, including disease-specific pathways. Results: During a median follow-up of 6.26 years, 1,182 (3.79%) participants developed first CVD event, 671 (2.15%) developed CVM. TyG index played crucial but different roles in all transitions from healthy to first CVD event, to CVM (HR = 1.162, 95% CI: 1.074, 1.257; HR = 1.148, 95% CI: 1.010, 1.305). When we further divided first CVD events into CHD, Stroke, and HF, we found that TyG index played different roles in disease-specific transitions even within the same transition stage (HR = 1.145, 95% CI: 1.029, 1.273; HR = 1.228, 95% CI: 1.085, 1.391; HR = 1.213, 95% CI: 1.057, 1.391). Conclusions: The TyG index is an independent predictor of dynamic progression toward cardiovascular multimorbidity, showing significant associations with atherosclerosis-driven conditions such as CHD and stroke but not with heart failure. These findings support its potential utility in risk stratification and preventive strategies across the cardiovascular disease continuum.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.